BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields

BlossomHill Therapeutics, a San Diego-based oncology biotech focused on small-molecule cancer drugs, has filed paperwork with the U.S. Securities and Exchange Commission (SEC) to pursue an initial public offering (IPO) of its common stock, aiming to raise up to about $100 million.

The company plans to list on the Nasdaq Global Select Market under the ticker symbol BLSM; the IPO is led by investment banks including J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright.

BlossomHill intends to use IPO proceeds to advance its early‑stage oncology pipeline, particularly its lead clinical asset BH‑30643, a first‑in‑class macrocyclic OMNI‑EGFR inhibitor in a global Phase 1/2 trial for EGFR‑mutant non‑small cell lung cancer (NSCLC), and to support a subsequent registrational‑type Phase 2 trial.

The company has raised roughly $257 million from private investors since its 2020 founding and is using the IPO as a way to ‘fertilize’ growth in the crowded cancer‑therapy market, where it aims to compete against established drugs such as AstraZeneca’s Tagrisso.